A Phase 1 interventional study of IPG11406 in Inflammatory Bowel Diseases, sponsored by Nanjing Immunophage Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Inflammatory Bowel Diseases with a site in China — 49 open to participants now, 53 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 112 studies in Inflammatory Bowel Diseases with a site in China, this one is the 42nd largest by enrollment of the 58 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 1, and was the 59th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →49 of the 112 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 12 · Phase 3 9
First in 2009; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 58 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 112 have an industry lead sponsor. The 10 most frequent:
Nanjing Immunophage Biotech Co., Ltd is the lead sponsor of 11 studies on the registry; 6 are open to participants now.
Nanjing Immunophage Biotech Co., Ltd has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
12 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 112 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and food effect of orally administered IPG11406 in healthy adult participants
This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, PK and food effect of orally administered IPG11406 in healthy adult participants. The study will involve two sequential parts: a single ascending dose (SAD) period (Part A) followed by a multiple ascending dose (MAD) period (Part B).
Part A Dose escalation will start from 0.5 mg. Currently, the 6 dose cohorts are Cohort 1 (0.5 mg), Cohort 2 (2 mg), Cohort 3 (6 mg), Cohort 4 (20 mg), Cohort 5 (40 mg), Cohort 6 (80 mg). About 42 healthy adult participants are being sequentially enrolled in 6 cohorts.
There are 6 participants in Cohort 1 to Cohort 3. In each cohort, 4 participants will receive IPG11406 and 2 participants will receive the placebo as per the randomization code.
Approximately 8 participants will be enrolled in Cohort 4 to Cohort 6 respectively; in each cohort, 6 participants will receive IPG11406 and 2 participants will receive the placebo as per the randomization code.
In each Cohort, 2 sentinel participants will be dosed at least 48 hours prior to the remaining participants. One sentinel will be dosed with IPG11406 and the other with a matching placebo. The remaining participants will be dosed only if no significant safety issues are identified in the sentinel participants. Doses and sampling intervals may be modified based on the PK and safety data that emerges throughout the study.
One of the SAD (Cohort 5 is tentatively to be selected, it may be modified based on the decision of SMC meeting.) cohorts will be selected to assess the effect of food on the pharmacokinetic parameters and referred to as the food effect (FE) cohort. Participants in this cohort will be requested to return to the clinical site to receive a second dose of IPG11406 or placebo after the administration of a meal, upon completion of the 4-day safety follow up period after their first dose. The second dose of IPG11406 or placebo will be administered following a standardized high fat meal (total calories approximately 800 to 1000 calories, with approximately 50% of total calories from fat).
Healthy participants will be screened within 28 days prior to dosing. Participants in the SAD cohorts (including FE cohort) will be admitted to the study site on Day -1 for a total of 6 days. Administration of a single dose of IPG11406 or the placebo will occur on Day 1 under fasted conditions (Following an overnight fast of at least 10 hours, subjects will receive a single dose of IPG11406 or placebo with 240 mL water. Water can be ingested as desired except for 1 hour pre-dose until one hour post dose.). Participants will be discharged on Day 5 following collection of samples for PK analyses and the completion of safety assessments. A follow-up visit will occur on Day 8.
Participants in the FE cohort will be admitted to the study site for at least 10 days for the 2 administrations of IPG11406. A washout of ≥ 4 days will be included between investigational product (IP) administrations. Administration of a single dose of IPG11406 or placebo will occur on Day 1 under fasted condition, and Day 6 (anticipated) under postprandial condition. Following completion of all safety assessments and sampling for PK analyses, subjects will be discharged on Day 10 (anticipated) after the second dose. There will be a follow-up visit on Day 13 (anticipated) after the single dose administration in each period.
Once the final participant in the cohort has completed the Day 5 assessments and been discharged, the Safety Monitoring Committee (SMC) will review cumulative blinded safety data (including follow-up visit data from preceding cohorts) and available PK data to determine the safety and tolerability of the study drug. If the dose level is determined to be safe and well-tolerated, the next dose cohort will be enrolled and randomized in preparation to receive the next dose level of IPG11406 or the placebo.
Part B Three dose levels (10 mg, 20 mg and 40 mg) are anticipated to be evaluated in the MAD, once daily. There will be approximately 8 subjects per cohort, 6 subjects will receive IPG11406 and 2 subjects will receive placebo per the randomization code.
For Cohort M1 (10 mg), the MAD phase will commence following the establishment of the safety and tolerability of Cohort 4 (20 mg) in the SAD. The SMC will evaluate the safety, tolerability and PK data obtained from the participants of cohort 4 in the SAD to determine if the Cohort M1 will be enrolled and randomized to receive the 10 mg multiple dose levels of IPG11406 or placebo.
For Cohort M2 (20 mg), the SMC will evaluate the safety, tolerability and PK data obtained from the participants of cohort 5 (40 mg) in the SAD as well as the safety and PK data from Cohort M1 to determine if the Cohort M2 will be enrolled and randomized to receive the 20 mg multiple dose levels of IPG11406 or placebo.
For Cohort M3 (40 mg), the SMC will evaluate the safety, tolerability and PK data obtained from the participants of cohort 6 (80 mg) in the SAD as well as the safety and PK data from Cohort M2 to determine if the Cohort M3 will be enrolled and randomized to receive the 40 mg multiple dose levels of IPG11406 or placebo.
All subjects will be screened within 28 days prior to dosing and will be admitted to the study site on Day -1. Dosing will start on the morning of Day 1 and will continue over a 10-day period at each dose level. Blood draws will be collected for the assessment of PK parameters. Participants will be discharged on Day 14 following completion of all PK sample collection and safety assessments. There will be a follow-up visit 7 days after the last dose.
Once the final participant in the cohort has completed the Day 14 assessments and been discharged, the SMC will review blinded cumulative safety data (including the follow-up visit data) and available PK data to determine the safety and tolerability of the study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria to be included in the study:
Demography
requirements for female subjects:
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from the study:
Medical history and clinical status
1. History of severe cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immune, dermatological, neurological, or psychiat ric disorders. 2. Abnormal chest X-ray findings. 3. Recurrent headache and/or migraine, recurrent nausea and/or vomiting (vomiting only: more than twice a month). 4. Blood donation within 2 months prior to inclusion is permitted, with no volume restrictions. 5. Symptomatic or asymptomatic orthostatic hypotension: defined as a drop in systolic blood pressure of ≥30 mmHg within 3 minutes when changing from supine to standing position. 6. History of drug allergy or confirmed allergic disease. 7. Known to be allergic to any component ofthe pharmaceutical preparation. 8. History of drug or alcohol abuse (regular daily alcohol intake exceeding 40 mL). 9. Heavy smokers (smoking 5 or more cigarettes per day). For light smokers (smoking fewer than 5 cigarettes per day), smoking should be discontinued during the trial period. 10. Individuals who consume excessive amounts oftea or coffee (more than 8 cups per day). 11. Take any medication within 14 days before inclusion or within 5 times the half-life or pharmacodynamic half-life ofthe medication; 12. Eat any citrus fruit (e.g. grapefruit, orange) or juice in the 5 days before selection. 13. Any vaccination within 28 days prior to inclusion and any injection of a biological agent (antibody or its derivative) within 4 months. 14. According to the investigators' assessment, the subjects may have poor compliance during the study or may not be able to cooperate due to language issues or intellectual developmental delays. 15. Participants were registered or had previously participated in any other clinical study involving a drug clinical trial or any other type of medical research within 3 months prior to enrollment or within the 5 half-life period (whichever is shorter). 16. Participants who could not be contacted in an emergency. 17. Researchers or associate researchers, research assistants, pharmacists, study coordinators, or other staff members who are directly or indirectly involved in the study, or anyone associated with the study site (including employees or immediate family members). 18. Any of the following tests are positive: surface antigen (HBsAg), hepatitis B core antigen (anti-HBcAg), anti- antibody, anti- 1 and 2 antibody (anti-HIV1 and anti-HIV2 Ab), or Treponema pallidum antibody. 19. Positive urine drug screening (amphetamines/methamphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opioids). 20. Alcohol test positive. 21. Subjects with difficulty in venous blood collection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 subjects in this cohort will receive a single dose of IPG11406 0.5 mg qd and 2 subjects will receive a single dose of placebo 0.5 mg qd orally.
Drug: IPG11406
4 subjects in this cohort will receive a single dose of IPG11406 2 mg qd and 2 subjects will receive a single dose of placebo 2 mg qd orally.
Drug: IPG11406
4 subjects in this cohort will receive a single dose of IPG11406 6 mg qd and 2 subjects will receive a single dose of placebo 6 mg qd orally.
Drug: IPG11406
6 subjects in this cohort will receive a single dose of IPG11406 20 mg qd and 2 subjects will receive a single dose of placebo 20 mg qd orally.
Drug: IPG11406
6 subjects in this cohort will receive a single dose of IPG11406 40 mg qd and 2 subjects will receive a single dose of placebo 40 mg qd orally.
Drug: IPG11406
6 subjects in this cohort will receive a single dose of IPG11406 80 mg qd and 2 subjects will receive a single dose of placebo 80 mg qd orally.
Drug: IPG11406
6 subjects in this cohort will receive a dose of IPG11406 10 mg qd and 2 subjects will receive a dose of placebo 10 mg qd orally from Day 1 to 10-day.
Drug: IPG11406
6 subjects in this cohort will receive a dose of IPG11406 20 mg BID and 2 subjects will receive a dose of placebo 20 mg BID orally from Day 1 to 10-day.
Drug: IPG11406
6 subjects in this cohort will receive a dose of IPG11406 40 mg qd and 2 subjects will receive a dose of placebo 40 mg qd orally from Day 1 to 10-day.
Drug: IPG11406
IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage:15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed. Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose. IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets
Also known as: IPG11406 Placebo
Safety Indicators:Adverse Event
Time frame: from first dose until end of follow-up, up to 17 days
Pharmacokinetic Indicators: Maximum Plasma Concentration (Cmax)
Peak concentration. It is directly obtained from the actual measured data of blood drug concentration-time. Steady-state maximum plasma concentration. Obtained directly from the measured plasma concentration-time data. Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.
Time frame: Up to 10 days
Pharmacokinetic Indicators: Area Under the Plasma Concentration Versus Time Curve (AUC)
From the last administration to the area under the blood concentration-time curve of the last measurable concentration. Calculated using the linear trapezoidal method: AUC(i, i+1) = (Ti+1 - Ti)(Ci + Ci+1) / 2, AUC0-t is the sum of all AUC(i, i+1). Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.
Time frame: Up to 10 days
Pharmacokinetic Indicators:Time to Maximum Concentration (Tmax)
Steady-state time to Cmax. Obtained directly from the measured plasma concentration-time data. Defined as the time of the first occurrence of Cmin, ss (when there are multiple maximum plasma concentrations), unless otherwise specified
Time frame: Up to 10 days
| Milestone | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD) | Placebo(MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 |
| Completed | 4 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD) | Placebo(MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adverse events | 1 | 3 | 2 | 3 | 4 | 5 | 4 | 6 | 5 | 6 | 5 |
Peak concentration. It is directly obtained from the actual measured data of blood drug concentration-time. Steady-state maximum plasma concentration. Obtained directly from the measured plasma concentration-time data. Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.
| ng/mL | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) |
|---|---|---|---|---|---|---|---|---|---|
| The Cmax data of the SAD group and the single-dose administration (D1) of the MAD group | 6.18 ± 1.812 | 27.31 ± 7.695 | 67.32 ± 23.190 | 271.48 ± 107.191 | 559.09 ± 131.992 | 1100.48 ± 506.708 | 141.76 ± 48.814 | 245.97 ± 44.820 | 552.85 ± 194.225 |
| The Cmax data of the MAD group after multiple administrations (D10) | — | — | — | — | — | — | 164.79 ± 66.293 | 284.4 ± 61.490 | 573.69 ± 168.739 |
From the last administration to the area under the blood concentration-time curve of the last measurable concentration. Calculated using the linear trapezoidal method: AUC(i, i+1) = (Ti+1 - Ti)(Ci + Ci+1) / 2, AUC0-t is the sum of all AUC(i, i+1). Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.
| h*ng/mL | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) |
|---|---|---|---|---|---|---|---|---|---|
| The AUC data of the SAD group and the single-dose administration (D1) of the MAD group | 25.16 ± 15.438 | 162.03 ± 70.235 | 569.74 ± 504.435 | 1353.59 ± 876.624 | 6609.03 ± 2892.938 | 11104.87 ± 7518.955 | 683.93 ± 357.850 | 752.81 ± 132.739 | 2736.13 ± 1397.644 |
| The AUC data of the MAD group after multiple administrations (D10) | — | — | — | — | — | — | 1627.45 ± 1274.247 | 993.57 ± 253.381 | 5321.30 ± 5011.186 |
Steady-state time to Cmax. Obtained directly from the measured plasma concentration-time data. Defined as the time of the first occurrence of Cmin, ss (when there are multiple maximum plasma concentrations), unless otherwise specified
| h | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) |
|---|---|---|---|---|---|---|---|---|---|
| TheTmax data of the SAD group and the single-dose administration (D1) of the MAD group | 2.63 ± 1.887 | 1.63 ± 0.250 | 3.13 ± 1.031 | 2.5 ± 1.483 | 2.25 ± 1.173 | 2.42 ± 1.463 | 2.67 ± 1.169 | 2.08 ± 1.530 | 2.17 ± 1.080 |
| The Tmax data of the MAD group after multiple administrations (D10) | — | — | — | — | — | — | 2.75 ± 1.037 | 2.17 ± 1.438 | 1.92 ± 1.242 |
Collected over from first dose until end of follow-up, up to 17 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (SAD - 0.5 mg) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Cohort 2 (SAD - 2 mg) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Cohort 3 (SAD - 6 mg) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Cohort 4 (SAD - 20 mg) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 5 (SAD - 40 mg) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Cohort 6 (SAD - 80 mg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 7 (MAD - 10 mg) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Cohort 8 (MAD - 20 mg) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Cohort 9 (MAD - 40 mg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Placebo(SAD) | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Placebo(MAD) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD) | Placebo(MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| InvestigationsInvestigations | 1/4 | 2/4 | 2/4 | 3/6 | 4/6 | 4/6 | 3/6 | 6/6 | 5/6 | 4/12 | 5/6 |
| Sinus bradycardiaCardiac disorders | 0/4 | 1/4 | 0/4 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/12 | 0/6 |
| Infection upper respiratoryInfections and infestations | 0/4 | 0/4 | 1/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 |
| Wandering pacemakerCardiac disorders | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/12 | 0/6 |
| Oropharyngeal painReproductive system and breast disorders | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/12 | 0/6 |
| DizzinessNervous system disorders | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/12 | 0/6 |
| Age, Categorical(Participants) | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD ) | Placebo(MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 66 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD ) | Placebo(MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 0 | 2 | 3 | 0 | 11 |
| Male | 4 | 4 | 3 | 6 | 5 | 3 | 5 | 6 | 4 | 9 | 6 | 55 |
| Race (NIH/OMB)(Participants) | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD ) | Placebo(MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 66 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| baseline weight(kg) | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD ) | Placebo(MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.58 ± 7.027 | 63.10 ± 7.935 | 58.15 ± 4.692 | 67.05 ± 6.961 | 62.78 ± 6.635 | 59.68 ± 9.639 | 64.08 ± 7.362 | 63.48 ± 5.553 | 61.30 ± 7.266 | 63.62 ± 7.793 | 72.08 ± 11.152 | 64.08 ± 8.028 |
| baseline height(cm) | Cohort 1 (SAD - 0.5 mg) | Cohort 2 (SAD - 2 mg) | Cohort 3 (SAD - 6 mg) | Cohort 4 (SAD - 20 mg) | Cohort 5 (SAD - 40 mg) | Cohort 6 (SAD - 80 mg) | Cohort 7 (MAD - 10 mg) | Cohort 8 (MAD - 20 mg) | Cohort 9 (MAD - 40 mg) | Placebo(SAD ) | Placebo(MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 170.50 ± 5.745 | 168.13 ± 8.459 | 161.00 ± 4.143 | 169.75 ± 4.345 | 167.75 ± 5.174 | 164.17 ± 9.042 | 169.58 ± 7.651 | 170.08 ± 7.493 | 164.33 ± 11.165 | 168.68 ± 10.034 | 172.42 ± 10.047 | 168.05 ± 8.212 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2024 to primary completion in Dec 2024, 10 months.
Results were first posted in Apr 2026, 1 year 3 months after primary completion.
Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 10 months is above that.
Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IPG11406
Nanjing Immunophage Biotech Co., Ltd